TD Private Client Wealth LLC Has $5.36 Million Stake in Johnson & Johnson (NYSE:JNJ)

TD Private Client Wealth LLC grew its stake in Johnson & Johnson (NYSE:JNJ) by 41.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 33,076 shares of the company’s stock after purchasing an additional 9,671 shares during the period. TD Private Client Wealth LLC’s holdings in Johnson & Johnson were worth $5,360,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Innealta Capital LLC acquired a new stake in Johnson & Johnson during the 2nd quarter worth approximately $27,000. Highline Wealth Partners LLC acquired a new position in shares of Johnson & Johnson during the third quarter worth $31,000. RPg Family Wealth Advisory LLC bought a new stake in shares of Johnson & Johnson in the third quarter worth $35,000. Mowery & Schoenfeld Wealth Management LLC increased its holdings in Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after purchasing an additional 91 shares during the period. Finally, Activest Wealth Management bought a new position in Johnson & Johnson during the 3rd quarter worth $40,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Down 0.2 %

Johnson & Johnson stock opened at $149.26 on Wednesday. The firm has a market capitalization of $359.35 billion, a price-to-earnings ratio of 21.60, a price-to-earnings-growth ratio of 2.66 and a beta of 0.51. The firm’s fifty day moving average price is $157.84 and its two-hundred day moving average price is $156.40. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.66 EPS. On average, equities research analysts predict that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th were paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.32%. The ex-dividend date of this dividend was Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Royal Bank of Canada increased their price target on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Wolfe Research initiated coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Wells Fargo & Company lifted their target price on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Finally, Citigroup upped their target price on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $175.40.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.